

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 13.08.2019

To,
Head Listing Compliance,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Security Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today i.e. **Tuesday, 13th August, 2018** (commenced at 05:00 P.M and concluded at 06:30 P.M.) has inter alia approved and passed the following resolutions:

1. The Board considered and approved draft of **Notice of Annual General Meeting** of the Company to be held on **Saturday, 28th September, 2019 at 10:45 A.M** at The Emerald Club, Supertech Emerald Court, Sector 93A Noida, Uttar Pradesh – 201304.
2. The Board considered and approved the **Board Report** for the year ended on **31st March, 2019**.
3. The Board considered and approved appointment of **M/s. Jain P & Associates, Practicing Company Secretaries**, as the **Scrutinizer** for conducting the e-voting process in a fair and transparent manner for the purpose of Annual General Meeting of the Company.
4. The Board fixed the Book Closure date from **Monday, 23rd September, 2019** to **Saturday, 28th September, 2019** (both days inclusive).
5. The Board fixed the cut-off date as **Sunday, 22nd September, 2019** for providing e-voting services.
6. The Board fixed E-Voting period for the Annual General Meeting to be from **25th September, 2019 (09:00 A.M.) to 27th September, 2019 (05:00 P.M)**

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

7. **Unaudited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended June 30, 2019.
8. Taking note of the **Limited Review Report** as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
9. Taking note of **Statement of Investor Complaints/Grievances** under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended June 30, 2019.


Kindly take the above information on your records.

Thanking you,

Yours faithfully,

For **Raymed Labs Limited**

Ajai Goyal
Whole Time Director
DIN: 02636418



A. Kay Mehra & Co.

CHARTERED ACCOUNTANTS

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

Limited Review Report for the quarter and period ended 30th June, 2019 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Raymed Labs Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Raymed Labs Limited** ("The Company") for the quarter ended 30th June, 2019, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting standard Specified under section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Kay Mehra & Co.
Chartered Accountants
F.R.N.:050004C



Deepak Suneja
CA Deepak Suneja
Partner
Membership No. 501957

Place: New Delhi
Date: 13.08.2019

CIN : L24111UP1992PLC014240

Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2019

Particulars	Amt. (In Lacs)			
	Quarter Ended		Year Ended	
	30th June, 2019	31st March, 2019	30th June, 2018	31st March, 2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from Operations	-	-	-	-
II. Other Income	0.33	0.33	0.30	1.26
III. Total Income (I +II)	0.33	0.33	0.30	1.26
IV. Expenses				
Cost of Material Consumed	-	-	-	-
Purchases of Stock-in-trade	-	-	-	-
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-	-	-	-
Employee Benefits Expenses	0.60	0.60	0.23	1.35
Finance Costs	-	-	-	-
Depreciation and amortisation expenses	0.15	0.16	0.16	0.64
Other Expenses	1.25	0.52	0.47	1.68
Total Expenses (IV)	2.00	1.27	0.86	3.66
V. Profit/(Loss) before exceptional items and tax (III- IV)	-1.67	-0.94	-0.56	-2.40
VI. Exceptional items				
	-	-	-2.95	2.95
VII. Profit/(Loss) before tax (V-VI)	-1.67	-0.94	-3.51	-5.35
VIII. Tax Expense				
(1) Current tax	-	-	-	-
(2) Deferred tax	-	-	-	-
(3) Previous Year Tax	-	-	-	-
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-1.67	-0.94	-3.51	-5.35
X. Profit/(Loss) from discontinued operations				
XI. Tax expense of discontinued operations	-	-	-	-
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)				
	-	-	-	-
XIII. Profit/(Loss) for the period (IX+XII)	-1.67	-0.94	-3.51	-5.35
XIV. Other Comprehensive Income				
(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
(B) (i) Items that will be classified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV. Total Comprehensive Income for the period (XIII+XIV)	-1.67	-0.94	-3.51	-5.35
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)				
XVI. Earnings per equity share (for continuing operation):				
(1) Basic	-0.04	-0.02	-0.08	-0.12
(2) Diluted	-0.04	-0.02	-0.08	-0.12
XVII. Earnings per equity share (for discontinued operation):				
(1) Basic	-	-	-	-
(2) Diluted	-	-	-	-
XVIII. Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	-0.04	-0.02	-0.08	-0.12
(2) Diluted	-0.04	-0.02	-0.08	-0.12

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 13.08.2019. The Statutory Auditors have carried out their review for the above results.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period classification.
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.
- The figures for the quarter ended March 31, 2019, are the balancing figures between audited figures in respect of the full financial year up to March 31, 2019 and the unaudited year to date figures up to December 31, 2018, being the date of the end of the third quarter of the previous year, which was subject to limited review.

For RAYMED LABS LIMITED

Ajai Goyal
Whole Time Director
DIN : 02636418

Date: 13.08.2019
Place : Noida